Abstract Library

#4283 Long-term efficacy and safety of peptide receptor radionuclide therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumour: Japanese phase I and phase I/II extension study

Introduction: PRRT with 177Lu-DOTATATE has been approved in Japan according to Japanese phase I and Phase I/II clinical trials. Primary end point of these clinical studies was safety and response rate, therefore, long-term efficacy and safety of PRRT for Japanese patients with NET are uncertain.

Conference:

Presenting Author: Ichikawa Y

Authors: Kobayashi N, Ono H, Okubo N, Akahoshi K, Kudo A,

Keywords: Neuroendocrine tumour, Peptide receptor radionuclide therapy, Japanese patients,

#3133 Establishment of neuroendocrine neoplasms organoid biobank enables genotype-phenotype mapping

Introduction: Gastroentero-pancreatic (GEP) neuroendocrine neoplasm (NEN) that consists of neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) is a lethal but under-investigated disease owing to its rarity. Incidence of this disease is recently increasing, and novel treatment is warranted. However, the establishment and application of GEP-NEN disease models have been limited.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Kawasaki K, Fujii M, Kudo A, Kanai T, Nakagawa H,

Keywords: organoids, CRISPR-Cas9, multi-omics analysis, gastrinoma, MiNEN,